BSE: 531521
DESH RAKSHAK AUSHDHALAYA LTD.
Manufactures Ayurvedic and herbal products and is based in Haridwar, having been established in 1901. The business is listed on BSE under scrip code 531521 and had FY26 revenue of Rs 7.1044 crore, with a net profit of Rs 0.5622 crore and an EBITDA margin of 19.6442%. Total assets stood at Rs 20.8884 crore at year-end. The cost structure is dominated by raw materials and packaging at 42% of revenue, followed by other operating expenses at 24% and employee costs at 14.5%, with depreciation at 6.1% and capex running at 14.4% of revenue. The company is small — 2,422 shareholders as of mid-2026 — and relies on working-capital lines, with outstanding borrowings of Rs 3.08 crore reported as of 31 March 2026. In September 2025, it raised Rs 2.77 crore through a preferential issue of 12.60 lakh shares at Rs 22 each, used for working capital (Rs 2.08 crore) and general corporate purposes (Rs 0.69 crore). The board has approved proposals to set up new branch offices within India and overseas, subject to regulatory approvals. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Ayurvedic and herbal products. Small-cap, niche Ayurvedic and herbal products manufacturer, working-capital-sensitive
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 6 | 6 | 6 | 6 | 7 |
| EBITDA (ex other income) | 1 | 1 | 1 | 1 | 1 |
| margin % | 19.2 | 21.5 | 21.3 | 19.9 | 19.5 |
| Owners' profit | 0 | 0 | 0 | 0 | 1 |
| EPS, as reported (₹) | 1.08 | 0.09 | 0.96 | 1.07 | 0.99 |
| ROE % · ROCE % | 5.2 · 5.9 | 4.4 · 6.7 | 4.5 · 7.0 | 4.8 · 6.6 | 4.2 · 5.8 |
| Debt / equity (x) | 0.46 | 0.45 | 0.29 | 0.31 | 0.21 |
| Cash from operations | 0 | 0 | 2 | (0) | (1) |
| Capex | (2) | 0 | (0) | (1) | (1) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 2 | 4 | 1 | 1 | 1 | 3 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.33 | 0.27 | 0.80 | 0.22 | 0.15 | 0.16 | 0.52 | 0.14 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 27.7 | 30.8 | 71 of 158 | 55% |
| P/B | 1.1 | 3.1 | 29 of 163 | 83% |
| ROCE | 4.1 | 10.8 | 134 of 183 | 27% |
| ROE | 4.2 | 9.8 | 121 of 166 | 27% |
| Debt / Equity | 0.2 | 0.2 | 98 of 166 | 41% |
| EBITDA margin | 29.4 | 17.5 | 38 of 165 | 77% |
| Revenue growth | (36.3) | 16.3 | 151 of 161 | 6% |
| Profit growth | (16.3) | 30.9 | 116 of 158 | 27% |
| Market cap | 15 | 806 | 170 of 181 | 6% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 14 Oct 2026 · Compliance Certificate for Dematerialisation Submitted for Q2 FY27 | compliance | minimal | — | — |
| 14 Oct 2026 · Routine compliance certificate for share dematerialization for Q2 FY27 | compliance | minimal | — | — |
| 27 Sept 2026 · Trading window closed from Oct 1, 2026 till Q2 results announcement | compliance | minimal | — | — |
| 26 Sept 2026 · AGM results: All 6 resolutions passed, including director pay revisions | board shareholder meetings | low | — | — |
| 25 Sept 2026 · Shareholders approve increase in managerial remuneration at AGM | management changes | medium | — | — |
| 25 Sept 2026 · Re-appointment of Mr. Arihant Kumar Jain as Whole-time Director at 45th AGM | management changes | medium | — | — |
| 25 Sept 2026 · 45th AGM concludes; six resolutions approved including pay hikes for directors | board shareholder meetings | low | — | — |
| 2 Sept 2026 · 45th AGM notice published in newspapers; meeting on September 25, 2026 | compliance | minimal | — | — |
| 2 Sept 2026 · Notice of 45th Annual General Meeting published in newspapers | compliance | minimal | — | — |
| 1 Sept 2026 · Weblink for FY 2025-26 Annual Report and 45th AGM Notice shared with shareholders | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.